Dow Up0.19% Nasdaq Up0.56%

Hospira Inc. (HSP)

-NYSE
58.53 Down 0.28(0.48%) 4:03PM EST
ProfileGet Profile for:
Hospira Inc.
275 North Field Drive
Lake Forest, IL 60045
United States - Map
Phone: 224-212-2000
Website: http://www.hospira.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drugs - Generic
Full Time Employees:17,000

Business Summary 

Hospira, Inc. provides injectable pharmaceutical drugs and infusion technologies to develop, manufacture, distribute, and market products worldwide. The company operates through Americas, EMEA, and APAC segments. It provides specialty injectable pharmaceuticals, which include approximately 200 injectable generic drugs in multiple dosages and formulations; and proprietary specialty injectables, such as Precedex, a proprietary drug for sedation. The company’s specialty injectable pharmaceuticals also comprises Biosimilars that include Retacrit, a biosimilar erythropoietin, which is primarily used in the treatment of anemia in dialysis and in certain oncology applications; Nivestim, a biosimilar filgrastim used for the treatment of low white blood cells in patients who have received a chemotherapeutic agent; and Inflectra, a biosimilar infliximab for the treatment of inflammatory conditions, including rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and psoriasis. In addition, it offers medication management products, including infusion pumps and dedicated administration sets; Hospira MedNet safety software system and related services; software applications and devices that support point-of-care medication administration; gravity administration sets; and other device products. Further, the company provides intravenous solutions and nutritional products; and contract manufacturing services, as well as develops proprietary pharmaceutical products, such as Dyloject, a post-operative pain management drug. It serves hospitals and alternate site providers, such as clinics, home healthcare providers, and long-term care facilities. The company has collaborative arrangements with Bioceuticals Arzneimittel AG to license and market Retacrit; and Q Core Medical, Ltd to market and distribute Sapphire, a multi-therapy infusion system. Hospira, Inc. was founded in 2003 and is headquartered in Lake Forest, Illinois.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Hospira Inc.

Corporate Governance 
Hospira Inc.’s ISS Governance QuickScore as of Nov 1, 2014 is 9. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 7; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. F. Michael Ball , 58
Chief Exec. Officer, Director and Member of Science & Technology Committee
3.09M0.00
Mr. Thomas E. Werner , 57
Chief Financial Officer and Sr. VP of Fin.
843.00K0.00
Mr. Matthew R. Stober , 46
Sr. VP of Operations
816.00K0.00
Dr. Sumant Ramachandra M.D., Ph.D., 45
Chief Scientific Officer and Sr. VP
873.00K0.00
Mr. Richard J. Davies , 52
Chief Commercial Officer and Sr. VP
865.00K0.00
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders